Detail

Study ID: Alliance A031701

Title:

A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Jonathan Bleeker, MD;Preston Steen, MD,Amit Panwalkar, MD;Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
Bladder
Stage:
Phase II
Status:
Active - Open to Accrual